BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...
Up 85% from its 1-year low with earnings forecast to grow 11% annually. How much value is left in this FTSE 100 star?
This FTSE 100 stock’s price has risen a long way from its 12-month low, but I think there could still be value left in it and ...
Forecast earnings growth of 17% a year but down 12%, is now the time for me to buy this heavyweight FTSE stock?
This FTSE medical technology stock has strong earnings growth projections, posted impressive 2024 results, and looks very undervalued to me.